Summary

The Non-opioid Analgesic Patch market will reach xxx Million USD in 2019 with CAGR xx% 2019-2025. The main contents of the report including:

market size and forecast

Regional market size, production data and export & import

Key manufacturers profile, products & services, sales data of business

market size by Major Application

market size by Major Type

Key manufacturers are included based on company profile, sales data and product specifications etc.:

GlaxoSmithKline Plc

Pfizer, Inc.

Teikoku Seiyaku Co., Ltd.

Mylan N.V.

Hisamitsu Pharmaceutical Co.,Inc

Acorda Therapeutics, Inc

Endo International plc

Allergan

Teh Seng Pharmaceutical Mfg

IBSA Institut Biochimque SA

Major applications as follows:

Hospital Pharmacies

Online Pharmacies

Independent Pharmacies & Drug Stores

Major Type as follows:

Lidocaine Patches

Diclofenac Patches

Methyl Salicylate Patches

Capsaicin Patches

Ketoprofen Patches

Others

Regional market size, production data and export & import:

Asia-Pacific

North America

Europe

South America

Middle East & Africa

Table of Contents
1 Market Overview
1.1 Scope of Statistics
1.1.1 Scope of Products
1.1.2 Scope of Manufacturers
1.1.3 Scope of Application
1.1.4 Scope of Type
1.1.5 Scope of Regions/Countries
1.2 Market Size
2 Regional Market
2.1 Regional Production
2.2 Regional Demand
2.3 Regional Trade
3 Key Manufacturers
3.1 GlaxoSmithKline Plc
3.1.1 Company Information
3.1.2 Product & Services
3.1.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.1.4 Recent Development
3.2 Pfizer, Inc.
3.2.1 Company Information
3.2.2 Product & Services
3.2.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.2.4 Recent Development
3.3 Teikoku Seiyaku Co., Ltd.
3.3.1 Company Information
3.3.2 Product & Services
3.3.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.3.4 Recent Development
3.4 Mylan N.V.
3.4.1 Company Information
3.4.2 Product & Services
3.4.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.4.4 Recent Development
3.5 Hisamitsu Pharmaceutical Co.,Inc
3.5.1 Company Information
3.5.2 Product & Services
3.5.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.5.4 Recent Development
3.6 Acorda Therapeutics, Inc
3.6.1 Company Information
3.6.2 Product & Services
3.6.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.6.4 Recent Development
3.7 Endo International plc
3.7.1 Company Information
3.7.2 Product & Services
3.7.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.7.4 Recent Development
3.8 Allergan
3.8.1 Company Information
3.8.2 Product & Services
3.8.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.8.4 Recent Development
3.9 Teh Seng Pharmaceutical Mfg
3.9.1 Company Information
3.9.2 Product & Services
3.9.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.10 IBSA Institut Biochimque SA
3.10.1 Company Information
3.10.2 Product & Services
3.10.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
4 Major Application
4.1 Hospital Pharmacies
4.1.1 Overview
4.1.2 Hospital Pharmacies Market Size and Forecast
4.2 Online Pharmacies
4.2.1 Overview
4.2.2 Online Pharmacies Market Size and Forecast
4.3 Independent Pharmacies & Drug Stores
4.3.1 Overview
4.3.2 Independent Pharmacies & Drug Stores Market Size and Forecast
5 Market by Type
5.By Lidocaine Patches
5.1 Lidocaine Patches
5.1.1 Overview
5.1.2 Lidocaine Patches Market Size and Forecast
5.2 Diclofenac Patches
5.2.1 Overview
5.2.2 Diclofenac Patches Market Size and Forecast
5.3 Methyl Salicylate Patches
5.3.1 Overview
5.3.2 Methyl Salicylate Patches Market Size and Forecast
5.4 Capsaicin Patches
5.4.1 Overview
5.4.2 Capsaicin Patches Market Size and Forecast
5.5 Ketoprofen Patches
5.5.1 Overview
5.5.2 Ketoprofen Patches Market Size and Forecast
5.6 Others
5.6.1 Overview
5.6.2 Others Market Size and Forecast
6 Price Overview
6.1 Price by Manufacturers
6.2 Price by Application
6.3 Price by Type
7 Conclusion